AR and posterior cortical atrophy: Therefore, the hallmark target for therapeutic agents in PCa involves the inhibition of androgen synthesis by preventing the transcription of AR activity either through chemical castration (i.e., abiraterone acetate) [9] or AR antagonists (i.e., enzalutamide) [10, 11].